Shots:
- The P-III TACKLE trial evaluates the safety & efficacy of AZD7442 (600mg, IM) as monothx. vs PBO in a ratio (1:1) in 903 outpatients aged ≥18yrs. who were non-hospitalized with COVID-19 & symptomatic for ≤7 days
- The trial met its 1EPs i.e., 50% reduction in risk of severe COVID-19 or death from any cause, was well tolerated. In prespecified analysis, 67% reduction in risk of severe COVID-19 or death from any cause
- Additionally, 90% of patients were at high risk of progression to sev COVID-19 including co-morbidities. The company will discuss data with the authorities. On Oct 5, 2021, the company had submitted a request to the US FDA for EUA of AZD7442 to treat prophylaxis of COVID-19
Click here to read full press release/ article | Ref: AstraZeneca | Image: Al Jazeera
The post AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19 first appeared on PharmaShots.
